Insider Selling: Establishment Labs (NASDAQ:ESTA) Director Sells 2,180 Shares of Stock

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Quiros Juan Jose Chacon sold 2,180 shares of Establishment Labs stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $66.26, for a total value of $144,446.80. Following the completion of the transaction, the director directly owned 1,107,504 shares in the company, valued at approximately $73,383,215.04. This represents a 0.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Friday, April 24th, Quiros Juan Jose Chacon sold 30,178 shares of Establishment Labs stock. The stock was sold at an average price of $65.78, for a total value of $1,985,108.84.
• On Thursday, April 23rd, Quiros Juan Jose Chacon sold 42,642 shares of Establishment Labs stock. The stock was sold at an average price of $65.43, for a total value of $2,790,066.06.
• On Tuesday, April 14th, Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock. The stock was sold at an average price of $65.23, for a total value of $2,446,125.00.
• On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The stock was sold at an average price of $60.08, for a total value of $214,786.00.
• On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The stock was sold at an average price of $60.39, for a total value of $2,048,730.75.

Establishment Labs Stock Performance

NASDAQ ESTA traded down $0.81 during trading on Monday, hitting $65.47. The company’s stock had a trading volume of 280,264 shares, compared to its average volume of 500,208. The company has a quick ratio of 2.00, a current ratio of 3.04 and a debt-to-equity ratio of 10.51. The firm has a 50 day moving average price of $66.33 and a 200 day moving average price of $65.35. The firm has a market cap of $1.92 billion, a P/E ratio of -37.63 and a beta of 1.08. Establishment Labs Holdings Inc. has a 52 week low of $28.89 and a 52 week high of $83.31.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.13. The company had revenue of $64.62 million for the quarter, compared to the consensus estimate of $63.80 million. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The company’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same period in the previous year, the business posted ($1.19) EPS. Equities research analysts forecast that Establishment Labs Holdings Inc. will post -0.86 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on ESTA shares. Needham & Company LLC lifted their price target on Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Stephens lifted their price objective on Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Canaccord Genuity Group lifted their price objective on Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a report on Friday, March 27th. Finally, BTIG Research lifted their price objective on Establishment Labs from $86.00 to $88.00 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.86.

Institutional Trading of Establishment Labs

Several institutional investors have recently modified their holdings of the company. Elevation Point Wealth Partners LLC acquired a new stake in shares of Establishment Labs during the 1st quarter worth approximately $209,000. Patriot Financial Group Insurance Agency LLC boosted its stake in Establishment Labs by 20.4% in the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 5,450 shares of the company’s stock valued at $309,000 after buying an additional 925 shares in the last quarter. Cannon Global Investment Management LLC acquired a new stake in Establishment Labs in the 1st quarter valued at $738,000. Brian Low Financial Group LLC boosted its stake in Establishment Labs by 10.2% in the 1st quarter. Brian Low Financial Group LLC now owns 4,598 shares of the company’s stock valued at $261,000 after buying an additional 424 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in Establishment Labs by 134.3% in the 1st quarter. SG Americas Securities LLC now owns 37,928 shares of the company’s stock valued at $2,154,000 after buying an additional 21,742 shares in the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.